Md. Asdullah

Abstract

Introduction: Oral submucous fibrosis (OSMF) is a scarring disease of the oral cavity that develops over time. Lycopene is a potent antioxidant found in tomatoes that has the best singlet oxygen quenching capability and a strong capacity to quench other free radicals in vitro of all the dietary carotenoids. A protein called hyaluronidase, which is found in mammalian sperm and testes, hydrolyzes hyaluronic acid to alter the permeability of connective tissue. Objective: To determine the effectiveness of lycopene and lycopenehyaluronidase in treating OSMF, as well as a comparison of their effectiveness. Materials and Methods : 45 people with OSMF were enrolled in the study and divided into three groups. Patients in Group A received two evenly divided doses of Lycored 16 mg twice daily for three months. Patients in Group B received LycoRed and a 1500 IU intralesional injection of hyaluronidase twice a week for three months. Patients in Group C received placebo pills. The patients were evaluated at the end of three months. We observed the opening of the mouth, visual examination, palpatory findings, and burning sensation. Results: For lycopene and lycopene–hyaluronidase combination, there was a statistically significant difference in mouth opening and burning sensation compared to placebo. Keywords: Lycopene, Hyaluronidase, Oral Submucous Fibrosis

Open full article page

Abstract

Background: Oral sub mucous fibrosis (OSF) is commonly seen in the Indian subcontinent affecting individuals of all age groups. It is a potentially malignant disorder caused almost exclusively by the use of smokeless form of tobacco products. The malignant transformation rates vary from 3 to 19%. The standard of care (SOC) in managing OSF includes habit cessation, intralesional steroid and hyaluronidase injections, and mouth opening exercises. Objectives: To evaluate the efficacy of rebamipide to reduce the oral burning sensation associated with OSMF as compared to coventional Betamethasone intralesional injection. Materials and Methods: After providing information about the study and obtaining consent, these individuals were divided into two groups of 15 each using random sampling method. Patients in the rebamipide group (group I) were prescribed 100 mg tablets of rebamipide thrice a day for 21 days. The other 15 patients (group II) were given SOC, intralesional betamethasone injection 4 mg/mL once a week for 4 weeks. Visual analog scale (VAS) with 11 points (0–10) was used to assess burning sensation in the first visit, and change in the burning sensation was assessed after every 7th day on VAS in both the groups. Results: The improvement in the VAS score in each visit was significant (p < 0> 0.05). The VAS score was significantly different between the rebamipide and betamethasone group (p > 0.05) in third & fourth visit. Conclusion: Our results showed that rebamipide was equally efficacious if not better than the betamethasone intralesional injections. Keywords: Betamethasone, Management, Oral submucous fibrosis, Rebamipide.

Open full article page